• EXO-OC ovarian cancer test achieved 100% sensitivity for early-stage disease
• CAR-exosome therapy killed 88% of triple-negative breast and lung cancer cells in vitro
• Advancing additional clinical studies and commercialization plans for both programs

Inoviq Ltd announced significant progress in its ovarian cancer diagnostic and CAR-exosome therapeutic programs during the June 2025 quarter. The EXO-OC ovarian cancer screening test demonstrated 100% sensitivity for detecting early-stage (I and II) disease with no false positives in a retrospective, blinded study. Overall, the test achieved 77% sensitivity at >99.6% specificity for detecting ovarian cancer across all stages. Inoviq is planning additional clinical validation studies and exploring commercialization partnerships to accelerate the development of EXO-OC as a non-invasive blood test for ovarian cancer screening. In the company's CAR-exosome therapeutic program, the first CAR-NK-exosome therapy showed exceptional efficacy, killing 88% of triple-negative breast cancer and non-small cell lung cancer cells in vitro within 96 hours. Inoviq is advancing the CAR-NK-exosomes to in vivo studies in a triple-negative breast cancer mouse model, with initial results expected in Q4 2025. The company also provided updates on its neuCA15-3 breast cancer monitoring test, which has been validated to detect breast cancer across all stages with 81% sensitivity and 93% specificity. Inoviq is working to transfer the test to a high-throughput platform and secure a commercialization partner. Financially, Inoviq had $6.5 million in cash at the end of the quarter and is focused on achieving key development and commercial milestones for its diagnostic and therapeutic programs over the next six months.

Inoviq did not provide any high-importance, price-sensitive forward-looking financial metrics in the announcement.

Over the next six months, Inoviq is focused on advancing its key programs: - Initiating additional clinical validation studies to support regulatory and commercial readiness for the EXO-OC ovarian cancer screening test - Delivering initial in vivo efficacy data for the CAR-NK-exosome therapy in a triple-negative breast cancer mouse model - Securing a strategic partnership to advance commercialization of the neuCA15-3 breast cancer monitoring test